TIME100 Most Influential Companies 2022: Pfizer conversationleaders.pfizer.com/post/7f5b8b69-…

We Must End Ageism in Cancer Clinical Trials - Scientific American scientificamerican.com/article/we-mus…

About 1 in every 10 cases of #colorectal #cancer is caused by a change in the BRAF gene. These patients may be eligible for the S2107 #clinicaltrial. Learn more at SWOG.org/S2107. Or call 1-800-4-CANCER. Ask about S2107. Funded by National Cancer Institute. #CRCSM #CRCTrialsChat

Just published! COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

If you are a #GI #Oncologist or #trainee -this Journal of Clinical Oncology Special Series is a must read!👇 Congratulations to Eileen M O’Reilly, Andrew Ko & all the contributors...fantastic one-stop resource 🙌OncoAlert ➡️Precision Medicine and Immunotherapy in GI Cancers ascopubs.org/doi/full/10.12…

Exciting study, led by the amazing Van Morris, MD that builds on our promising Phase 1B/2 work at MD Anderson Cancer Center.

Our #WomenInMelanoma group (ring-led by AIM at Melanoma Foundation) turned out to support Sapna Patel discussion S1801 #neoadjuvant vs #adjuvant Pembro for stage III/IV melanoma.

Mini-orals lower GI! clara montagut v #ESMO22 Josep Tabernero discussing safety lead-in of Breakwater study @elena_elez

🔥BREAKWATER safety lead in: mBRAV V600E #coloncancer at #EMSO22🔥 ✅Encorafenib (E) & cetuximab (C) + FOLFOX/FOLFIRI 👉1st line: ORR 67/60%, mPFS 9.9/nr, DOR 7.6mo 👉2nd line: ORR 50/61%, PFS 9.7/nr, DOR nr 👉SAEs 33.3/48.1% 👇overall promising ESMO - Eur. Oncology OncoAlert

SLI presented Josep Tabernero #ESMO2022

Like what you see? You can easily share these National #ColorectalCancerAwarenessMonth graphics on your social media—just click and share! Help spread the message👉bit.ly/23MarchSPK

With the proposed acquisition of @SeagenGlobal, we will have the potential to deliver the next generation of breakthroughs using an innovative #cancer-fighting technology called antibody-drug conjugates (ADCs). Check out this video to learn more: on.pfizer.com/3J8XCmh

At #ASCO23, we’re sharing our poster presentation on the safety and efficacy results from the phase 2 PHAROS study in BRAF V600E-mutant metastatic non-small cell #LungCancer.

No oncologist would treat breast cancer without knowing -- or at least trying to test -- ER/PR/her2 status At #asco23 it's time to apply that standard in advanced GI oncology Upper GI: claudin 18.2, FGFR2b, her2, MSI/MMR, PDL1, TMB Colorectal: braf, extended ras, her2, MSI/MMR

GI is on #TumorBoardTuesday this week! Help spread the word! Michelle Warner Katrina Pedersen, MD, MS @rashidlui Nadia Saoudi González Leticia Moreira @joaquincubiella James Good Shima Ghavimi Marta Rodriguez Castells Ján Slopovský Bowel Cancer UK De Meulder Sofie @karen_gc_cincin Ahmed Zakari Fight Colorectal Cancer

BREAKING: Today, the U.S. FDA granted approval of our combination therapy for the treatment of adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer (#NSCLC). Learn more: on.pfizer.com/48NwVPX #LungCancer

BREAKING: Today at #ASCO24, we unveiled new 5-year progression-free survival data in previously untreated, ALK+ advanced non-small cell #LungCancer (NSCLC): on.pfizer.com/452jgTN

Change the Odds with Patrick Dempsey and the American Cancer Society conversationleaders.pfizer.com/post/7e18b922-…

Lung Cancer Awareness Month conversationleaders.pfizer.com/post/936a6949-…